(Sharecast News) - PureTech Health announced the launch of Celea Therapeutics on Tuesday, a new company focused on developing treatments for serious respiratory diseases, led by former Teva North America chief executive Sven Dethlefs.
The London-listed firm said Celea's lead programme is deupirfenidone (LYT-100), a phase three-ready candidate for idiopathic pulmonary...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE